TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03459885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (with eXimia magnetic stimulator and Dantec Keypoint® electroneuromyography device)
Description: Paired associative stimulation (PAS) administered several times per week for 8 weeks to lower limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
Study: NCT04147780

Intervention type: PROCEDURE
Intervention: Sentinel node biopsy
Description: Sentinel node biopsy, radiotracer (mandatory) and blye dye (optional). Scintigraphy.

Intervention type: PROCEDURE
Intervention: Sentinel node biopsy
Description: Sentinel node biopsy, radiotracer (mandatory) and blye dye (optional). Scintigraphy.

Intervention type: PROCEDURE
Intervention: Sentinel node biopsy
Description: Sentinel node biopsy, radiotracer (mandatory) and blye dye (optional). Scintigraphy.

Intervention type: PROCEDURE
Intervention: Sentinel node biopsy
Description: Sentinel node biopsy, radiotracer (mandatory) and blye dye (optional). Scintigraphy.
Study: NCT02132429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 333
Description: Oral administration available in varying dose strength.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo containing no active drug
Study: NCT00438009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coxsackievirus A21
Description: Two doses of drug, separated by 48 hours
Study: NCT00775190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ortho tricyclen
Description: brand name oral contraceptive

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trinessa
Description: generic oral contraceptive
Study: NCT04667130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis
Description: Preventive program included informations of the possibilities of physiotherapy in the treatment of multiple sclerosis focused on fatigue management - recommending lifestyle changes. Program included a the treatment of psychosomatic, viscerosomatic functional disorders by reflexively poor connection through the locomotor system using computer kinesiology, psychotherapy, manual therapy - where patients are corrected into a postural position and the joints are functionally centred, and aerobic exercise to influence fatigue and improve the performance of the cardiovascular system.
Study: NCT03692299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces Boulardii Oral Tablet
Description: Saccharomyces boulardii 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces Boulardii Oral Tablet
Description: Saccharomyces boulardii 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months
Study: NCT00693901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR)
Description: CBPR will involve park advisory boards and community members in the research process, including the park assessments and data analysis. The assessment research will be used to inform use of discretionary funds for park programming and facilities in the hopes of increasing community physical activity. Park directors will be provided with analysis of descriptive information and community feedback to help improve outreach, park programming, and features to attract more park users and increase physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Director-only
Description: Park directors will be provided with descriptive information on park use and community feedback. They will also receive assistance on how to improve outreach, programming, and park features that will increase park use and physical activity. These parks will not take part in any assessments.
Study: NCT01376804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valganciclovir [Valcyte]
Description: Oral, daily for up to 200 days.
Study: NCT00420771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: For the first week, one 400 mg Gabapentin capsule taken 3 times per day. For the second week, two 400 mg Gabapentin capsules taken 3 times per day. For the third week through the eighth week, three 400 mg Gabapentin capsules taken 3 times per day. For the ninth and last week, two 400 mg Gabapentin capsules taken 3 times per day for 3 days, then one 400 mg Gabapentin capsule taken 3 times per day for 4 days. Placebo study medication appears identical to active medication and is prescribed with an identical dosing schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator appears identical to active medication and is prescribed with an identical dosing schedule with a maximum dose of 400mg taken three times per day
Study: NCT04004195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2327949
Description: A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2327949
Description: A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2327949
Description: A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2327949
Description: A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)
Study: NCT01949818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangzhengxiaoji capsule combined with CHOP regimen
Description: Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)Yangzhengxiaoji capsule ,1.56g,Tid,p.o,d7-21, Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen
Description: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5
Study: NCT04427267

Intervention type: OTHER
Intervention: Personal protective equipment from biological hazard
Description: Includes: isolation clothing, mask, eyewear, overshoes
Study: NCT00560196

Intervention type: OTHER
Intervention: Observation

Intervention type: OTHER
Intervention: Observation

Intervention type: OTHER
Intervention: Observation
Study: NCT00641667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) to 100 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is as per Investigator's discretion (maximum applied dose is 300 mcg/hr) up to Day 7 and then dose is fixed for next 3 days that is Day 10 (end of treatment period).
Study: NCT04271397

Intervention type: OTHER
Group type: OTHER
Intervention: Multiple blood samples
Description: Patients with active tuberculosis will have 5 research-specific blood samples: V1, (baseline) immediately before initiating anti-tuberculosis treatment, then 4 samples during anti-tuberculosis treatment and follow-up, i.e. at 48 hours (V2), 15 days (V3), 2 months (V4) and 6 months (V5) after initiation of treatment. The total volume of each sample will be 20 mL for a total of 100 mL.

Intervention type: OTHER
Group type: OTHER
Intervention: Single blood sample
Description: Patients with Latent tuberculosis infection will have a single specific sample of 14 mL.
Study: NCT03782506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Music Therapy
Description: Ten 45-minutes individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. Each session involves learning and practicing music-based techniques for the self-management of pain, anxiety, stress, mood, fatigue, and sleep disturbance as these are common opioid withdrawal symptoms. Psychoeducation about opioid tapering is provided and tapering challenges experienced by the patient will be actively addressed through music-based interventions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal-based support
Description: Ten 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears. As in the IMT protocol, psychoeducation about opioid tapering will be included and will be considered the only active treatment factor for this intervention.
Study: NCT03713346

Intervention type: OTHER
Group type: OTHER
Intervention: Lactose free milk
Description: Single dose of lactose free milk

Intervention type: OTHER
Group type: OTHER
Intervention: Lactose free milk
Description: Single dose of lactose free milk

Intervention type: OTHER
Group type: OTHER
Intervention: Jersey milk
Description: Single dose of jersey milk

Intervention type: OTHER
Group type: OTHER
Intervention: Jersey milk
Description: Single dose of jersey milk

Intervention type: OTHER
Group type: OTHER
Intervention: High A1 β-casein milk
Description: Single dose of high A1 β-casein milk (commercial milk)

Intervention type: OTHER
Group type: OTHER
Intervention: High A1 β-casein milk
Description: Single dose of high A1 β-casein milk (commercial milk)

Intervention type: OTHER
Group type: OTHER
Intervention: High A2 β-casein milk
Description: Single dose of A2 β-casein milk

Intervention type: OTHER
Group type: OTHER
Intervention: High A2 β-casein milk
Description: Single dose of A2 β-casein milk
Study: NCT01181349

Intervention type: OTHER
Intervention: Neuromuscular Blocking Agent (NMBA)
Description: While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug\[s\]) are not specified in the protocol.

Intervention type: OTHER
Intervention: Neuromuscular Blocking Agent (NMBA)
Description: While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug\[s\]) are not specified in the protocol.
Study: NCT00712439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Extended Release tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02131506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib, Caelyx
Description: Lapatinib, Caelix: Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is defined as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq \& Lapatinib 1000 mg die; dose level 1, Caelyx 30 mg/mq \& Lapatinib 1250 mg die; dose level 2, Caelyx 30 mg/mq \& Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq \& Lapatinib 1500 mg die
Study: NCT02338271

Intervention type: OTHER
Group type: OTHER
Intervention: autologous adipose derived mesenchymal stem cell
Description: autologous adipose derived mesenchymal stem cell (2 x 10\^7 cells/mL /vial or 4 x 10\^7 cells/mL /vial) and Tissuefill (hyaluronic acid derivatives) 1mL/syringe
Study: NCT03549767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Springfusor
Description: Springfusor for administration of magnesium sulphate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Pritchard regimen. Magnesium sulphate is administered using hospital practice
Study: NCT03298035

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP as mode for apnea prevention
Description: With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIPPV as rescue mode for apnea prevention
Description: With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
Study: NCT02038933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT01759446

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo taken first
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic H/A taken first
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vycavert taken first
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic H/A plus i taken first
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic H/A plus p taken first
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses
Study: NCT02817009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: The social worker for the parent support group addresses culturally specific questions and adopts culturally acceptable strategies for setting limits and promoting healthy behaviors, engaging the group as a whole and building peer support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Session
Description: Nutrition sessions will focus on how to make traditional Latin American foods healthier, including the sharing of recipes and learning what foods to buy in local supermarkets. Home visits by the nutritionist assists with family-centric strategies for healthier eating in their urban Latino households, including those with large extended families.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Session
Description: 45 minutes physical activity session to promote healthy behaviors
Study: NCT03763877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Oral capsule
Study: NCT00528034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Description: Procedure where a very small amount (less than one tenth of a teaspoon) of a radioactive material is injected around the edge of the tumor in the vagina, followed immediately by the scan. The scan is done before the patient has surgery or begins radiation therapy.
Study: NCT02915822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Chevron/Akin osteotomy
Description: Minimally invasive technique for hallux valgus correction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Scarf/Akin osteotomy
Description: Open technique for Hallux Valgus correction
Study: NCT03537404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Narlaprevir
Description: 100 mg, film-coated tablets, taken as 200 mg per os daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: 100 mg, film-coated tablets, taken as 200 mg per os daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: 100 mg, film-coated tablets, taken as 200 mg per os daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg, film-coated tablets, taken as 100 mg per os daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg, film-coated tablets, taken as 100 mg per os daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg, film-coated tablets, taken as 100 mg per os daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: 300 mg, film-coated tablets, taken as 300 mg per os daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: 300 mg, film-coated tablets, taken as 300 mg per os daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400 mg, film-coated tablets, taken as 400 mg per os daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg, film-coated tablets, taken as 400 mg per os daily
Study: NCT01523093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Orally Disintegrating Tablets 8mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Orally Disintegrating Tablets 8mg
Study: NCT06416124

Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometric assessment
Description: A total of 43 anthropometric variables (complete profile) will be assessed following the guidelines of the International Society for the Advancement of Kinanthropometry. All measurements will be taken on the right side of the body. The full anthropometric profile will be undertaken in duplicate to establish retest reliability. If the difference between duplicate measures exceeds 5% for skinfolds or 1% for all other variables, a third measurement will be taken, but only after the full profile has been completed in duplicate. The mean of duplicate or median of triplicate anthropometric measurements will be used for all subsequent analysis. The intra-evaluator technical error of measurement (TEM) was calculated according to the 1996 protocol of Pederson and Gore.
Study: NCT00183482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Group Cognitive Behavioral
Description: Groups of families receive training in parenting and children learn about coping in ten weekly sessions and then three monthly sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Information
Description: Families are mailed written materials that describe depression and stress in families with a depressed parent.
Study: NCT04613037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation
Description: Fecal Microbial Transplantation in adults with Atopic Dermatitis
Study: NCT04259996

Intervention type: PROCEDURE
Intervention: PROGESTERONE AND ESTRADIOL SERUM CONCENTRATION MEASUREMENT
Description: The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer.

Intervention type: PROCEDURE
Intervention: PROGESTERONE AND ESTRADIOL SERUM CONCENTRATION MEASUREMENT
Description: The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer.
Study: NCT03443570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: given with a fixed dose of 500 mg administered as an intravenous infusion every two weeks, for 2 times totally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: given with a fixed dose of 500 mg administered as an intravenous infusion every two weeks, for 2 times totally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: given subcutaneous injection at a fixed dose of 2.0 mg weekly, for 4 times totally
Study: NCT03847896

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose)
Description: Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 160/180 micrograms (μg), given as 2 inhalations of BDA MDI 80/90 μg, four times a day (QID)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose)
Description: Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 80/180 micrograms (μg), given as 2 inhalations of BDA MDI 40/90 μg, four times a day (QID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide metered dose inhaler / BD MDI 160 µg
Description: Budesonide pressurized metered dose inhaler (BD MDI) 160 micrograms (μg), given as 2 inhalations of BD MDI 80 μg, four times a day (QID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol sulfate metered dose inhaler / AS MDI 180 μg
Description: Albuterol sulfate pressurized metered dose inhaler (AS MDI) 180 micrograms (μg), given as 2 inhalations of AS MDI 90 μg, four times a day (QID)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo metered-dose inhaler / Placebo MDI
Description: Placebo pressurized metered dose inhaler (Placebo MDI), given as 2 inhalations of Placebo MDI, four times a day (QID)
Study: NCT03970317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Broad Band Light
Description: Broad Band Light Device
Study: NCT03473509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CKD Registry
Description: Health Service intervention